The stock of The Chemours Company (NYSE:CC) increased by $0.5 on Friday to finish at $32.74, up 1.55 percent. The last five days have seen an average of 808,860 shares of common stock traded. 21 times new highs were reached in the current year, with a gain of $2.12. The average number of shares traded over the last 20 days was 1,223,780, while the average volume over the last 50 days totaled 1,435,904.
CC stock dropped -13.73% since last month. On 08/22/23, the company’s shares reached a one-month low of $31.70. The stock touched a high of $39.05 on 07/20/23, after rallying from a low of $23.58 in 52 weeks. The price of CC stock has risen by 6.92% or $2.12 this year, reaching a new high 21 times. Still, the stock price is down -16.16% from the 52-week high.
Insider Transactions
CC stock investors should be aware that The Chemours Company (CC) stock had its last reported insider trading activity 80 days ago on Jun 09. On Jun 09, President and CEO Newman Mark acquired 7,661 shares at $34.63 each. This transaction resulted in the insider spending $265,300. On Jun 09, Scarborough Alvenia sold 5,125 shares at a price of US$32.30. After the transaction, the insider now owns 13,890 shares. SVP, Chief Enterprise Transfor Abbott Matthew S had earlier sold 8,912 shares on Jun 08 for $34.20 a share. The transaction was completed for $304,790.
Valuation Metrics
Beta for the stock is 1.98. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 0.76, the price-to-book (PB) ratio of 6.04, and the price-to-cash flow ratio of 41.51.
Company paid $0.25 per share in dividends, remained unchanged from $0.25 last year. A $0.08 dividend increase was reported on Friday August 3 2018.
Financial Health
For the three months ended June 29, The Chemours Company’s quick ratio was 0.90, while its current ratio was 1.50, indicating its inability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 4.46, and the total debt to equity ratio is 4.49. As far as profitability goes, gross margin for the trailing twelve months is 22.40% percent. The Chemours Company’s EBITDA margin for the year ended June 29 was 16.16%, whereas its operating margin stood at 1.00% for the same period. Based on annual data, it had gross profit of $1.62 billion and revenue of $6.79 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. CC’s return on assets (ROA) during the last 12 months has been -1.10%. There was a 13.00% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -8.00%.
Earnings Surprise
According to The Chemours Company’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $1.64 billion, while revenues fell by -16.56% to $1.54 billion. It was predicted that The Chemours Company’s quarterly earnings would be $1.1, but it ended up being $1.07, beating the consensus by 2.80%. EBITDA was -$316.0 million for the quarter. At the end of The Chemours Company’s most recent quarter ended June 29, its liabilities totaled 6.85 billion, while its total debt was $3.88 billion. Equity owned by shareholders amounts to $148.08 million.
Technical Picture
Here’s a quick look at The Chemours Company’s (CC) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 34.52%, suggesting the stock is Neutral, with a 23.46% historical volatility rate.
The stochastic %K and %D were 11.17% and 7.36% respectively, while the average true range (ATR) was 0.94. Based on the 14-day stochastic reading of 19.12%, the RSI (14) reading is 35.40%. On the 9-day MACD Oscillator, the stock is at -0.05, and the 14-day reading is at -1.05.
Analyst Ratings
The Chemours Company (NYSE: CC) was downgraded by BofA Securities to a a Neutral rating in its latest research report. The stock was previously rated as a a Buy. Analysts have assigned The Chemours Company (CC) an Hold rating. CC is a stock that is recommended for selling by 2 brokerage firms, while 8 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 3 others recommend it as a buy.
What is CC’s price target for the next 12 months?
The current consensus forecast for the stock is between $29.00 and $53.00, with a median target price of $39.00. In analyzing these forecasts, the average price target given by analysts for The Chemours Company (CC) is $39.55.
